VOGX

Vogenx Inc

14.53

Oct 16 • 3:59 PM ET -1.52 (-9.47%)

14.53

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Oct 15, 4:40 PMVogenx announces it has initiated EMERGE, a Phase 2b randomized, double-blind, placebo-controlled trial of mizagliflozin in patients with post-bariatric hypoglycemia.

Held by: VXF VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-
Market Cap	215.84M
Enterprise Value	216.52M
Income	-
Sales	-
Book/sh	-0.12
Cash/sh	0.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 12, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	1136.00
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.06
Current Ratio	0.06
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.09
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	35.75%
Insider Trans	0.00%
Inst Own	12.95%
Inst Trans	75.11%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-27.82%
SMA50	-41.69%
SMA200	-41.69%
Trades

Shs Outstand	14.86M
Shs Float	9.54M
Short Float	0.28%
Short Ratio	0.15
Short Interest	0.03M
52W High	38.41 -62.17%
52W Low	12.95 12.20%
Volatility	12.47% 15.64%
ATR (14)	2.90
RSI (14)	30.72
Beta	-
Rel Volume	0.47
Avg Volume	179.14K
Volume	84,594

Perf Week	-17.26%
Perf Month	-57.43%
Perf Quarter	-
Perf Half Y	-
Perf YTD	11.77%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.50
Target Price	48.50
Prev Close	16.05
Price	14.53
Change %	-9.47%

Oct-15-26 04:35PM	Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia (ACCESSWIRE) -9.47%
Oct-09-26 08:00AM	Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer (ACCESSWIRE)
Sep-22-26 09:00AM	Vogenx Appoints Ken Toombs to Board of Directors (ACCESSWIRE) -9.93%
Aug-17-26 12:25PM	Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering (PR Newswire) +6.56%
Aug-13-26 04:35PM	Vogenx Announces Closing of Initial Public Offering (ACCESSWIRE) +8.38%

Vogenx, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the discovery and development of treatments for serious metabolic and gastrointestinal diseases. The company was founded by James Green, William Wilkison, and Steven Delmar on February 5, 2021 and is headquartered in Raleigh, NC.

PresidentMr. James Green

CFOMr. Steven R. Delmar

Chief Scientific OfficerDr. William Wilkison Ph.D.

VOGX

Vogenx Inc

Upgrade your Finviz experience